Keelara Abiraj
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 29, 2020
89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 03, 2017
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 15, 2015
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Journal: The Lancet. Oncology
Published: March 23, 2015
¹¹¹In-anti-F4/80-A3-1 antibody: a novel tracer to image macrophages.
Journal: European journal of nuclear medicine and molecular imaging
Published: March 11, 2015
Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRP-R) positive tumors.
Journal: Journal of medicinal chemistry
Published: December 05, 2014
Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts?
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 29, 2014
Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 11, 2014
Last Updated: 09/26/2026